Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sharmilee Gnanapavan

Showing results (1-10 of 76) with videos related to

Pageof 8
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 8, 2021
The multiple sclerosis prodrome is just unspecific symptoms in radiologically isolated syndrome patients - YesSharmilee Gnanapavan
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 13, 2018
Hidden cost of pembrolizumab therapySharmilee Gnanapavan
Current Topics in Behavioral Neurosciences|December 16, 2014
Developing Biomarkers for MSSharmilee Gnanapavan, Gavin Giovannoni
Multiple Sclerosis and Related Disorders|April 17, 2015
Neural cell adhesion molecules in brain plasticity and diseaseSharmilee Gnanapavan, Gavin Giovannoni
International Journal of MS Care|January 11, 2021
Letter to the Editor: Consensus Statement on Neurofilament Proteins in Multiple Sclerosis Under Development by Consortium of Multiple Sclerosis Centers (CMSC) Expert PanelMark Freedman, Sharmilee Gnanapavan
Journal of Neurology|March 29, 2011
Surviving stiff-person syndrome: a case reportSharmilee Gnanapavan, Angela Vincent, Gavin Giovannoni
Multiple Sclerosis and Related Disorders|June 5, 2025
The practical uses of serum neurofilament light chain as a biomarker in multiple sclerosisJada Coker, Anisha Doshi, Sharmilee Gnanapavan
Advances in Clinical Chemistry|August 24, 2024
Neurofilaments in neurologic diseaseChristina Mousele, David Holden, Sharmilee Gnanapavan
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 25, 2017
Science is 1% inspiration and 99% biomarkersNicolas Dubuisson, Fabiola Puentes, Gavin Giovannoni, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|November 12, 2025
Long-term effectiveness and cost-effectiveness of testing for alemtuzumab antidrug antibodies to guide treatment in multiple sclerosis: a modelling studyTimothy Jamieson, Florian Tomini, Sharmilee Gnanapavan, et al.
Pageof 8

Showing results (1-10 of 76) with videos related to

Sort By:
Pageof 8
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 8, 2021
The multiple sclerosis prodrome is just unspecific symptoms in radiologically isolated syndrome patients - YesSharmilee Gnanapavan
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 13, 2018
Hidden cost of pembrolizumab therapySharmilee Gnanapavan
Current Topics in Behavioral Neurosciences|December 16, 2014
Developing Biomarkers for MSSharmilee Gnanapavan, Gavin Giovannoni
Multiple Sclerosis and Related Disorders|April 17, 2015
Neural cell adhesion molecules in brain plasticity and diseaseSharmilee Gnanapavan, Gavin Giovannoni
International Journal of MS Care|January 11, 2021
Letter to the Editor: Consensus Statement on Neurofilament Proteins in Multiple Sclerosis Under Development by Consortium of Multiple Sclerosis Centers (CMSC) Expert PanelMark Freedman, Sharmilee Gnanapavan
Journal of Neurology|March 29, 2011
Surviving stiff-person syndrome: a case reportSharmilee Gnanapavan, Angela Vincent, Gavin Giovannoni
Multiple Sclerosis and Related Disorders|June 5, 2025
The practical uses of serum neurofilament light chain as a biomarker in multiple sclerosisJada Coker, Anisha Doshi, Sharmilee Gnanapavan
Advances in Clinical Chemistry|August 24, 2024
Neurofilaments in neurologic diseaseChristina Mousele, David Holden, Sharmilee Gnanapavan
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 25, 2017
Science is 1% inspiration and 99% biomarkersNicolas Dubuisson, Fabiola Puentes, Gavin Giovannoni, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|November 12, 2025
Long-term effectiveness and cost-effectiveness of testing for alemtuzumab antidrug antibodies to guide treatment in multiple sclerosis: a modelling studyTimothy Jamieson, Florian Tomini, Sharmilee Gnanapavan, et al.
Pageof 8